Fate Therapeutics, Inc. (NASDAQ:FATE) recovered 66.25% of its value since hitting low of $2.40. The recent move of -4.77% drop pushed the stock to close at $3.99 when trading ended on 11/15/2017. At recent session, the prices were hovering between $3.99 and $4.2916. This company shares are 100.5% off its target price of $8 and the current market capitalization stands at $167.1M. The recent change has given its price a -6.16% deficit over SMA 50 and -29.75% deficit over its 52-week high. The stock witnessed -2.21% declines, 32.12% gains and 4.18% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found FATE’s volatility during a week at 6.86% and during a month it has been found around 7.28%.Fate Therapeutics, Inc. (FATE) Top Holders
Institutional investors currently hold around $106 million or 77% in FATE stock. Look at its top three institutional owners. Franklin Resources Inc owns $25.46 million in Fate Therapeutics, Inc., which represents roughly 15.24% of the company’s market cap and approximately 24.02% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 3,970,785 shares of the stock are valued at $16.64 million. The third largest holder is Polaris Venture Management Co. V, L.L.C., which currently holds $10.36 million worth of this stock and that ownership represents nearly 6.2% of its market capitalization.
At the end of 09/30/2017 reporting period, 37 institutional holders increased their position in Fate Therapeutics, Inc. (NASDAQ:FATE) by some 1,097,612 shares, 28 decreased positions by 2,293,473 and 14 held positions by 21,984,012. That puts total institutional holdings at 25,375,097 shares, according to SEC filings. The stock grabbed 20 new institutional investments totaling 771,089 shares while 5 institutional investors sold out their entire positions totaling 465,524 shares.Fate Therapeutics, Inc. (NASDAQ:FATE) Insider Trades
Multiple company employees have indulged in significant insider trading. Fate Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Scientific Officer Shoemaker Daniel D has sold 13,225 shares of Fate Therapeutics, Inc. (FATE) in trading session dated Oct. 16, 2017. These shares are worth $51,181 and were traded at $3.87 each. The SEC filing shows that Tahl Cindy performed a sale of 8,091 shares. The General Counsel and Secretary disposed these shares by way of transaction on Oct. 16, 2017. The company’s shares were given away at $3.85 per share worth to an income of some $31,150 on account of Tahl Cindy.
President and CEO, Wolchko J Scott, sold 17,168 common shares of Fate Therapeutics, Inc. (FATE) in the open market. In a transaction dated Oct. 16, 2017, the shares were put up for sale at an average price of $3.88, raking in a sum of $66,612. After this sale, 124,881 common shares of FATE are directly owned by the insider, with total stake valued at $498,275.
In the transaction dated Nov. 23, 2016, the great number of shares acquired came courtesy the Chief Medical Officer; Storgard Chris added a total of 37,593 shares at an average price of $2.66, amounting to approximately $99,997. The insider now directly owns 46,683 shares worth $186,265.Fate Therapeutics, Inc. (FATE) Analyst Guide
Several analysts have released their opinion on Fate Therapeutics, Inc. (NASDAQ:FATE), with 4 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.2 average brokerage recommendation.